{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:46:41Z","timestamp":1774633601900,"version":"3.50.1"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T00:00:00Z","timestamp":1626912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Surgical treatment is the only possible cure for cholangiocarcinoma (CCA) at present. However, the high recurrence rate of postoperative CCA leads to a very poor prognosis for patients, effective postoperative chemotherapy is hence the key to preventing the recurrence of CCA. The sensitivity of CCA to cytotoxic chemotherapy drugs and targeted drugs varies from person to person, and therefore, the screening of sensitive drugs has become an important topic after CCA surgeries. Patient-Derived tumor Xenograft models (PDX) can stably retain the genetic and pathological characteristics of primary tumors, and better simulate the tumor microenvironment of CCA. The model is also of great significance in screening therapeutic targeted drugs after CCA, analyzing predictive biomarkers, and improving signal pathways in prognosis and basic research. This paper will review the current established methods and applications of the patient-derived tumor xenograft model of cholangiocarcinoma, aiming to provide new ideas for basic research and individualized treatment of cholangiocarcinoma after surgery.<\/jats:p>","DOI":"10.3389\/fonc.2021.628636","type":"journal-article","created":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T16:25:10Z","timestamp":1626971110000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The Application Progress of Patient-Derived Tumor Xenograft Models After Cholangiocarcinoma Surgeries"],"prefix":"10.3389","volume":"11","author":[{"given":"Jun","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyao","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanjiao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuewen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: Current Knowledge and New Developments","volume":"11","author":"Blechacz","year":"2017","journal-title":"Gut Liver"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert Consensus Document: Cholangiocarcinoma: Current Knowledge and Future Perspectives Consensus Statement From the European Network for the Study of Cholangiocarcinoma (Ens-Cca)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2016.11.001","article-title":"Surveillance in Cholangiocellular Carcinoma","volume":"30","author":"Wirth","year":"2016","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis","volume":"72","author":"Clements","year":"2020","journal-title":"J Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12885-019-5391-0","article-title":"Molecular Pathogenesis of Cholangiocarcinoma","volume":"19","author":"Labib","year":"2019","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.06.005","article-title":"Chemoresistance and Chemosensitization in Cholangiocarcinoma","volume":"1864","author":"Marin","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2174\/1389450116666150223121508","article-title":"Molecular Bases of Chemoresistance in Cholangiocarcinoma","volume":"18","author":"Marin","year":"2017","journal-title":"Curr Drug Targets"},{"key":"B9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40360-018-0223-4","article-title":"Effect of \u03b2-Eudesmol on NQO1 Suppression-Enhanced Sensitivity of Cholangiocarcinoma Cells to Chemotherapeutic Agents","volume":"19","author":"Srijiwangsa","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e0191593","DOI":"10.1371\/journal.pone.0191593","article-title":"Prognostic and Predictive Role of EGFR Pathway Alterations in Biliary Cancer Patients Treated With Chemotherapy and Anti-EGFR","volume":"13","author":"Peraldo-Neia","year":"2018","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-3725","article-title":"The IGF2\/IR\/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma","volume":"24","author":"Vaquero","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27739","article-title":"Excision Repair Cross-Complementing gene-1, Ribonucleotide Reductase Subunit M1, Ribonucleotide Reductase Subunit M2, and Human Equilibrative Nucleoside Transporter-1 Expression and Prognostic Value in Biliary Tract Malignancy","volume":"119","author":"Fisher","year":"2013","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.6153","article-title":"Survival Pathway of Cholangiocarcinoma Via AKT\/mTOR Signaling to Escape RAF\/MEK\/ERK Pathway Inhibition by Sorafenib","volume":"39","author":"Yokoi","year":"2018","journal-title":"Oncol Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2017.12.006","article-title":"Molecular Bases of the Poor Response of Liver Cancer to Chemotherapy","volume":"42","author":"Marin","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications","volume":"9","author":"Churi","year":"2014","journal-title":"PloS One"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12253-018-0491-8","article-title":"Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis","volume":"26","author":"Lendvai","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4539","article-title":"Genetic Heterogeneity in Cholangiocarcinoma: A Major Challenge for Targeted Therapies","volume":"6","author":"Brandi","year":"2015","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jhep.2012.06.017","article-title":"Liver Specific Deletion of CYLDexon7\/8 Induces Severe Biliary Damage, Fibrosis and Increases Hepatocarcinogenesis in Mice","volume":"57","author":"Urbanik","year":"2012","journal-title":"J Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/14.11.2415","article-title":"Promotion of Cholangiocarcinogenesis in the Hamster Liver by Bile Duct Ligation After Dimethylnitrosamine Initiation","volume":"14","author":"Thamavit","year":"1993","journal-title":"Carcinogenesis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2018.03.026","article-title":"Animal Models of Cholangiocarcinoma","volume":"1865","author":"Loeuillard","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B21","article-title":"Effect of Cholecystokinin on Human Cholangiocarcinoma Xenografted Into Nude Mice","volume":"45","author":"Hudd","year":"1985","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","article-title":"Applications of Patient-Derived Tumor Xenograft Models and Tumor Organoids","volume":"13","author":"Yoshida","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cells8060621","article-title":"Patient-Derived Xenograft Models of Breast Cancer and Their Application","volume":"8","author":"Murayama","year":"2019","journal-title":"Cells"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0922","article-title":"Jq1 Induces Dna Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma","volume":"17","author":"Garcia","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17779","article-title":"Targeting SHP-1-STAT3 Signaling: A Promising Therapeutic Approach for the Treatment of Cholangiocarcinoma","volume":"8","author":"Hu","year":"2017","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/bf00454264","article-title":"The Potential of the Nude Mouse Xenograft Model for the Study of Head and Neck Cancer","volume":"239","author":"Braakhuis","year":"1984","journal-title":"Arch Otorhinolaryngol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12885-016-2136-1","article-title":"Establishment of a Patient-Derived Intrahepatic Cholangiocarcinoma Xenograft Model With KRAS Mutation","volume":"16","author":"Cavalloni","year":"2016","journal-title":"BMC Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-0959-6","article-title":"Biobanking of Human Pancreas Cancer Tissue: Impact of Ex-Vivo Procurement Times on RNA Quality","volume":"17","author":"Rudloff","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"9904","DOI":"10.1038\/s41598-019-46410-6","article-title":"Development of Orthotopic Tumour Models Using Ultrasound-Guided Intrahepatic Injection","volume":"9","author":"McVeigh","year":"2019","journal-title":"Sci Rep"},{"key":"B30","article-title":"Establishment of Pancreatic Cancer Patient-Derived Xenograft Models and Comparison of the Differences Among the Generations","volume":"11","author":"Xu","year":"2019","journal-title":"Am J Transl Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0147113","DOI":"10.1371\/journal.pone.0147113","article-title":"Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts","volume":"11","author":"Lipner","year":"2016","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050496","article-title":"Establishment of Highly Transplantable Cholangiocarcinoma Cell Lines From a Patient-Derived Xenograft Mouse Model","volume":"8","author":"Vaeteewoottacharn","year":"2019","journal-title":"Cells"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2009.171","article-title":"Generation of Orthotopic and Heterotopic Human Pancreatic Cancer Xenografts in Immunodeficient Mice","volume":"4","author":"Kim","year":"2009","journal-title":"Nat Protoc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2015.080","article-title":"An Orthotopic Mouse Model of Hepatocellular Carcinoma With Underlying Liver Cirrhosis","volume":"10","author":"Reiberger","year":"2015","journal-title":"Nat Protoc"},{"key":"B35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.tranon.2018.09.008","article-title":"Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftment","volume":"12","author":"Hernandez","year":"2019","journal-title":"Transl Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e5981","DOI":"10.7717\/peerj.5981","article-title":"A Systematic Review of the Validity of Patient Derived Xenograft (PDX) Models: The Implications for Translational Research and Personalised Medicine","volume":"6","author":"Collins","year":"2018","journal-title":"PeerJ"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular Targeted Therapies: Ready for \u201cPrime Time\u201d in Biliary Tract\u00a0Cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J Hepatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14100","article-title":"Medical Treatment for Cholangiocarcinoma","author":"Adeva","year":"2019","journal-title":"Liver Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New Horizons for Precision Medicine in Biliary Tract Cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discovery"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-918","article-title":"Anti-Cancer Effect and Gene Modulation of ET-743 in Human Biliary Tract Carcinoma Preclinical Models","volume":"14","author":"Peraldo-Neia","year":"2014","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.05.017","article-title":"Antitumor Effect of FGFR Inhibitors on a Novel Cholangiocarcinoma Patient Derived Xenograft Mouse Model Endogenously Expressing an FGFR2-CCDC6 Fusion Protein","volume":"380","author":"Wang","year":"2016","journal-title":"Cancer Lett"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.698472","article-title":"A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma","volume":"291","author":"Rizvi","year":"2016","journal-title":"J Biol Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13575","article-title":"Gene and microRNA Modulation Upon Trabectedin Treatment in a Human Intrahepatic Cholangiocarcinoma Paired Patient Derived Xenograft and Cell Line","volume":"7","author":"Peraldo Neia","year":"2016","journal-title":"Oncotarget"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1159\/000490210","article-title":"RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing Nf-Kb-Mediated Cell Apoptosis","volume":"47","author":"Yu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-18-0158","article-title":"Yap Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity","volume":"16","author":"Sugihara","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.026","article-title":"Fibroblast Growth Factor Receptor Inhibition Induces Loss of Matrix MCL1 and Necrosis in Cholangiocarcinoma","volume":"68","author":"Kabashima","year":"2018","journal-title":"J Hepatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.26246","article-title":"Platelet-Derived Growth Factor Regulates YAP Transcriptional Activity Via Src Family Kinase Dependent Tyrosine Phosphorylation","volume":"119","author":"Smoot","year":"2018","journal-title":"J Cell Biochem"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30704","article-title":"Dependency of Cholangiocarcinoma on Cyclin D-Dependent Kinase Activity","volume":"70","author":"Sittithumcharee","year":"2019","journal-title":"Hepatology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41389-019-0153-z","article-title":"Novel Tumor Suppressor Role of miRNA-876 in Cholangiocarcinoma","volume":"8","author":"Ursu","year":"2019","journal-title":"Oncogenesis"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-019-04109-z","article-title":"Patient-Derived Xenografts Can Be Reliably Generated From Patient Clinical Biopsy Specimens","volume":"23","author":"Hernandez","year":"2019","journal-title":"J Gastrointestinal Surg"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.12122\/j.issn.1673-4254.2020.10.10","article-title":"[Ponatinib Inhibits Growth of Patient-Derived Xenograft of Cholangiocarcinoma Expressing FGFR2-CCDC6 Fusion Protein in Nude Mice]","volume":"40","author":"Wu","year":"2020","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02749-7","article-title":"Anlotinib Suppresses Tumor Progression Via Blocking the VEGFR2\/PI3K\/AKT Cascade in Intrahepatic Cholangiocarcinoma","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"eaay0152","DOI":"10.1126\/scitranslmed.aay0152","article-title":"PTEN Status Determines Chemosensitivity to Proteasome Inhibition in Cholangiocarcinoma","volume":"12","author":"Jiang","year":"2020","journal-title":"Sci Transl Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100068","article-title":"Biliary Tract Cancer Patient-Derived Xenografts: Surgeon Impact on Individualized Medicine","volume":"2","author":"Leiting","year":"2020","journal-title":"JHEP Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04079-z","article-title":"Evaluation of NUC-1031: A First-in-Class ProTide in Biliary Tract Cancer","volume":"85","author":"Arora","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"18489","DOI":"10.1038\/s41598-020-75578-5","article-title":"Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Suppresses Cholangiocarcinoma Growth by Targeting CDK2\/5\/9","volume":"10","author":"Saqub","year":"2020","journal-title":"Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-0505-4","article-title":"Crenigacestat, a Selective NOTCH1 Inhibitor, Reduces Intrahepatic Cholangiocarcinoma Progression by Blocking VEGFA\/DLL4\/MMP13 Axis","volume":"27","author":"Mancarella","year":"2020","journal-title":"Cell Death Differ"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.39779","article-title":"Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma","volume":"16","author":"Chen","year":"2020","journal-title":"Int J Biol Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01844-z","article-title":"Plasmalemma Vesicle-Associated Protein Promotes Angiogenesis in Cholangiocarcinoma Via the DKK1\/CKAP4\/PI3K Signaling Pathway","volume":"40","author":"Wang","year":"2021","journal-title":"Oncogene"},{"key":"B60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/cancers13092051","article-title":"A Novel Multidrug-Resistant Cell Line From an Italian Intrahepatic Cholangiocarcinoma Patient","volume":"13","author":"Peraldo-Neia","year":"2021","journal-title":"Cancers"},{"key":"B61","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jitc-2020-001946.#","article-title":"Tumor-Associated Neutrophils and Macrophages Interaction Contributes to Intrahepatic Cholangiocarcinoma Progression by Activating STAT3","volume":"9","author":"Zhou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2017.04.023","article-title":"The Logic of the 26S Proteasome","volume":"169","author":"Collins","year":"2017","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-Like Protein Conjugation and the Ubiquitin-Proteasome System as Drug Targets","volume":"10","author":"Bedford","year":"2011","journal-title":"Nat Rev Drug Discovery"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3892\/or.2012.1767","article-title":"A Possible Connection Between Adhesion Regulating Molecule 1 Overexpression and Nuclear Factor Kappa B Activity in Hepatocarcinogenesis","volume":"28","author":"Yang","year":"2012","journal-title":"Oncol Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-014-9663-4","article-title":"ADRM1 Gene Amplification Is a Candidate Driver for Metastatic Gastric Cancers","volume":"31","author":"Jang","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms14023094","article-title":"Amplification Target Adrm1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer","volume":"14","author":"Fejzo","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1600067113","article-title":"Notch3 Drives Development and Progression of Cholangiocarcinoma","volume":"113","author":"Guest","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.07.020","article-title":"Inhibit Globally, Act Locally: CDK7 Inhibitors in Cancer Therapy","volume":"26","author":"Cao","year":"2014","journal-title":"Cancer Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30152-2","article-title":"FGFR Inhibitors for Advanced Cholangiocarcinoma","volume":"21","author":"Yang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"Tas-120 Overcomes Resistance to ATP-Competitive Fgfr Inhibitors in Patients With FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discovery"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01563-z","article-title":"YAP and the Hippo Pathway in Cholangiocarcinoma","volume":"54","author":"Sugihara","year":"2019","journal-title":"J Gastroenterol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.06.008","article-title":"Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct Idh-Mutant Molecular Profiles","volume":"19","author":"Farshidfar","year":"2017","journal-title":"Cell Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3596","article-title":"Kras(G12D) and p53 Mutation Cause Primary Intrahepatic Cholangiocarcinoma","volume":"72","author":"O\u2019Dell","year":"2012","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11429","article-title":"Comprehensive Genomic Profile of Cholangiocarcinomas in China","volume":"19","author":"Tian","year":"2020","journal-title":"Oncol Lett"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9726-5","article-title":"Mutations of Key Driver Genes in Colorectal Cancer Progression and Metastasis","volume":"37","author":"Huang","year":"2018","journal-title":"Cancer Metastasis Rev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS Mutations and Acquired Resistance to anti-EGFR Therapy in Colorectal Cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.14694\/EDBK_175679","article-title":"Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches","volume":"37","author":"Atreya","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30254","article-title":"Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(01)02118-4","article-title":"Making Decisions Through Myc","volume":"490","author":"Nasi","year":"2001","journal-title":"FEBS Lett"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.03.044","article-title":"A Mouse Model of Cholestasis-Associated Cholangiocarcinoma and Transcription Factors Involved in Progression","volume":"141","author":"Yang","year":"2011","journal-title":"Gastroenterology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1042\/CBI20110099","article-title":"Down-Regulation of c-Myc Expression Inhibits the Invasion of Bile Duct Carcinoma Cells","volume":"35","author":"Li","year":"2011","journal-title":"Cell Biol Int"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nature09504","article-title":"Selective Inhibition of BET Bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.126","article-title":"The BET Bromodomain Inhibitor JQ1 Suppresses Growth of Pancreatic Ductal Adenocarcinoma in Patient-Derived Xenograft Models","volume":"35","author":"Garcia","year":"2016","journal-title":"Oncogene"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-020-0505-4","article-title":"Crenigacestat, a Selective NOTCH1 Inhibitor, Reduces Intrahepatic Cholangiocarcinoma Progression by Blocking VEGFA\/DLL4\/MMP13 Axis","volume":"27","author":"Mancarella","year":"2020","journal-title":"Cell Death Differ"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080889","article-title":"Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (Pdx) Models","volume":"8","author":"Okada","year":"2019","journal-title":"Cells"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nature12626","article-title":"Influence of Tumour Micro-Environment Heterogeneity on Therapeutic Response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32662","article-title":"The Fidelity of Cancer Cells in PDX Models: Characteristics, Mechanism and Clinical Significance","volume":"146","author":"Shi","year":"2020","journal-title":"Int J Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky984","article-title":"Pdx Finder: A Portal for Patient-Derived Tumor Xenograft Model Discovery","volume":"47","author":"Conte","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2019.12.10","article-title":"Immune Checkpoint Inhibitor Therapy in Biliary Tract Cancer (Cholangiocarcinoma)","volume":"9","author":"Jakubowski","year":"2020","journal-title":"Chin Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315201","article-title":"Development of a New Patient-Derived Xenograft Humanised Mouse Model to Study Human-Specific Tumour Microenvironment and Immunotherapy","volume":"67","author":"Zhao","year":"2018","journal-title":"Gut"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1037-4","article-title":"Evaluation of Anti-PD-1-based Therapy Against Triple-Negative Breast Cancer Patient-Derived Xenograft Tumors Engrafted in Humanized Mouse Models","volume":"20","author":"Rosato","year":"2018","journal-title":"Breast Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-019-0518-z","article-title":"Characterization of Immune Responses to Anti-PD-1 Mono and Combination Immunotherapy in Hematopoietic Humanized Mice Implanted With Tumor Xenografts","volume":"7","author":"Capasso","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.628636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T16:25:16Z","timestamp":1626971116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.628636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,22]]},"references-count":92,"alternative-id":["10.3389\/fonc.2021.628636"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.628636","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,22]]},"article-number":"628636"}}